Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 long-term safety and durability study of ALKS 3831 in schizophrenia, schizophreniform disorder, or bipolar I disorder
MOH_2017-08-10_000717Phase 3Recruiting
- Sponsor
- Alkermes
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olanzapine + samidorphan in schizophrenia, schizophreniform disorder and bipolar I disorder, sponsored by Alkermes. Primary endpoints: Long-term safety, Tolerability and 1 more. Started Jul 2017; status: recruiting.
02
Drugs
olanzapine + samidorphan
03
Conditions
schizophreniaschizophreniform disorderbipolar I disorder
Beyond the preview
Go deeper on MOH_2017-08-10_000717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-10_000717.